Evidence map›Paper›PMID 42045621›Full record

ArticleAlimentary pharmacology & therapeutics2026

One-Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real-World GETAID Study.

Nicolas Richard, Philippe Seksik, Romain Altwegg, Maria Nachury, David Laharie, Stéphane Nancey, Benoît Coffin, Anne-Laure Pelletier, Mathieu Uzzan, Aurélien Amiot and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Editorial: Upadacitinib in Perianal Crohn's Disease.Alimentary pharmacology & therapeutics · 2026
    Article
  5. Editorial: Upadacitinib in Perianal Crohn's Disease. Authors' Reply.Alimentary pharmacology & therapeutics · 2026
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nicolas RichardDepartment of Gastroenterology, University Rouen Normandie, INSERM, ADEN UMR1073, "Nutrition, Inflammation and Microbiota-Gut-Brain Axis", CHU Rouen, Rouen, France.ORCID https://orcid.org/0000-0003-1294-5039
Philippe SeksikDepartment of Gastroenterology, CRSA, Sorbonne Université, INSERM UMRS-938, Gut, Liver & Microbiome Research (GLIMMER) FHU, APHP, Saint-Antoine Hospital, Paris, France.
Romain AltweggDepartment of Gastroenterology, CHU of Montpellier, Montpellier, France.
Maria NachuryUniversity of Lille, INSERM, Lille University Hospital, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
David LaharieDepartment of Gastroenterology, CHU de Bordeaux, Haut-Lévêque Hospital, University of Bordeaux, Bordeaux, France.ORCID https://orcid.org/0000-0002-4753-6676
Stéphane NanceyDepartment of Gastroenterology, Lyon-Sud Hospital, CHU of Lyon, Lyon, France.
Benoît CoffinClinique Ambroise Paré Hartman, Institut des MICI, Neuilly sur Seine, France.
Anne-Laure PelletierDepartment of Gastroenterology, CHU Bichat-Claude Bernard, Paris, France.ORCID https://orcid.org/0000-0003-4055-7615
Mathieu UzzanGastroenterology Department, Henri Mondor Hospital, Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Paris Est Créteil University UPEC, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France.ORCID https://orcid.org/0000-0002-7761-2879
Aurélien AmiotDepartment of Gastroenterology, Hôpitaux Universitaires Bicêtre, AP-HP, Université Paris Saclay, Le Kremlin Bicêtre, France.ORCID https://orcid.org/0000-0001-6676-1222
Morgane AmilDepartment of Gastroenterology, La Roche Sur Yon Hospital, La Roche Sur Yon, France.
Lucine VuittonDepartment of Gastroenterology, UMR Right Inserm 1098, University Marie et Louis Pasteur, Franche-Comté, Besançon, France.
Mathurin FumeryDepartment of Gastroenterology, Amiens University Hospital, And PeriTox, University of Picardie, Amiens, France.
Anne BozonDepartment of Gastroenterology, CHU of Montpellier, Montpellier, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionUpadacitinib (UPA) is effective for treating luminal Crohn's disease (CD), but data on perianal CD (pCD) remain limited.

methodsAll consecutive patients with active pCD (primary and/or secondary lesions) treated with UPA across 13 French centres between September 2022 and August 2025 were included in a retrospective cohort study. Clinical remission was defined as absence of fistula drainage (spontaneous or on gentle pressure) and healing of anal ulcerations without initiation of new therapy. Clinical response was defined as ≥ 50% improvement in fistulas and/or ulcerations based on physician assessment. Clinical outcomes were analysed using non-responder imputation, and magnetic resonance imaging (MRI) outcomes as observed.

resultsAmong the 59 patients included, 43 (73%) had fistulizing pCD and 16 (27%) isolated anal ulcerations. All patients were previously exposed to at least one biologic and 79% of those with fistulizing pCD underwent prior perianal surgery. In patients with fistulizing pCD, clinical remission was achieved in 11/43 (26%) and 11/43 (26%) patients at 6 and 12 months, respectively, clinical response in 21/43 (49%) and 13/43 (30%) patients. At 12 months, MRI response was documented in 9/13 (69%) and MRI remission in 1/13 (8%) patients with fistulizing pCD. Among patients with fistulizing pCD, no factors predicted clinical remission. Among patients with isolated anal ulcerations, complete healing occurred in 5/16 (31%) at 3 months, 4/16 (25%) at 6 months and 4/16 (25%) at 12 months.

conclusionIn this real-world cohort of refractory pCD, UPA achieved clinical remission in one-quarter of patients at 1 year.

Indexed as

Crohn DiseaseHeterocyclic Compounds, 3-RingAdultFemaleFranceHumansMagnetic Resonance ImagingMaleMiddle AgedRectal FistulaRemission InductionRetrospective StudiesTreatment OutcomeHeterocyclic Compounds, 3-RingupadacitinibCrohn's diseasefistulizing perianal Crohn's diseaseupadacitinib

Identifiers

PMID42045621
PMCPMC13309209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.